All News

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Holistic wellness and helping patients manage the toxins in their outside life are just a few of the focuses at Wobbly Arrow Wellness.

The data highlight a new role for pregnancy-associated plasma protein A, known as PAPP-A, in gestational diabetes, with translational potential as both a diagnostic tool and therapeutic target, according to the investigators.

Modern technology is crucial to the provision of home infusions.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Symptoms of fibrous dysplasia include bone pain, swelling, bone deformity, bone and fractures.

Terrasil Shingles Skincare helps to alleviate pain, itching, burning, and irritation associated with shingles.

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.

Avoiding COVID-19 battle fatigue requires intentional efforts by employees and supervisors.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

The cancer care system lags in comparison to other chronic health conditions in this key area.

Judy Neville, program director of the college of pharmacy and pharmacy technician program at the University of Nebraska Medical Cancer, discusses what to look forward to for the AAPT conference in 2022.

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.

Universal school-based depression screening shows promise addressing mental health conditions in students.

Cold sores are usually caused by herpes simplex virus type 1 and herpes simplex virus type 2.

Bevespi is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

The Bruise Remedy gel contains a botanical formula to relieve and soothe bruising.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses what stands out as the biggest challenge from the past year and what role USP and pharmacists had in overcoming that challenge.

The approval of Vyvgart is the first for a therapy designed to reduce pathogenic IgGs, an underlying driver of gMG.

Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

The first and only orally disintegrating tablet form of glycopyrrolate, the product will be launched in early 2022.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the work of the NIH ORWH impacts pharmacy practice.

The Board of Trustees of APhA addresses 5 areas in their statement, including importance of wellbeing, root causes of pharmacist burnout, pharmacy benefit manager issues, need for provider status, and some potential solutions.